The Current State:
Alzheimer’s disease, a worldwide crisis, is on the rise. In the United States alone a new Alzheimer’s patient is diagnosed each minute, over 5 million patients suffer from Alzheimer’s, loved ones dedicate billions of unpaid caregiver hours, and the societal cost is in the hundreds of billions of dollars.
And yet, while enormous energy and investment has gone into the development of new Alzheimer’s solutions, the failure rate of R&D focused on Alzheimer’s is staggering, leaving patients and physicians with few treatment choices.
The one development approach proven successful and resulting in efficacious medicines is based on the “hypocholinergic hypothesis.” The brain communicates with itself through the release of neurotransmitters such as acetylcholine across trillions of synapses, the small gaps between neurons. Alzheimer’s disease progressively weakens acetylcholine neurotransmission. As acetylcholine communication decreases, human cognition becomes increasingly impaired along with much of what makes us who we are, including our memory, knowledge, judgment, reasoning, mood and language.
Today the standard-of-care treatment for Alzheimer’s disease is acetylcholinesterase inhibitors (AChEIs), drugs that have been proven to improve the amount and duration-of-action of acetylcholine in the brain. Unfortunately, current AChEIs are only modestly effective in improving cognition because side effects such as retching, diarrhea, nausea and vomiting limit their dosing to sub-effective levels.
The Chase Solution:
Chase’s goal is to resolve the dose-limiting side effects of current AChEIs so that the potential to greatly improve cognition in Alzheimers patients is finally unlocked. Chase has developed patent-protected new approaches to AChEIs paired with complementary peripheral cholinergic-blocking pharmaceuticals. Chase believes that this new approach to AChEIs will allow the dosing of cognition-enhancing AChEIs at much higher doses, increasing acetylcholine concentrations in the brain to optimal levels and significantly improving cognition without the limiting side effects of first generation AChEIs. These next-generation formulations from Chase Pharmaceuticals offer the possibility to profoundly restore cognition in Alzheimer’s patients.
Chase has developed patent-protected, fixed-dose combinations of AChEIs paired with complementary peripheral cholinergic-blocking pharmaceuticals. Chase is creating next-generation AChEI formulations that should be tolerated at significantly higher doses, increasing acetylcholine concentrations in the brain to optimal levels and significantly improving cognition and a patient's ability to function.
Chase currently has three programs in clinical development. Its lead candidate, CPC-201, an oral combination of donepezil, the current standard-of-care AChEI treatment, and a peripherally acting cholinergic blocker, will enter Phase 3 clinical development for the treatment of Alzheimer’s disease in 2016. CPC-201 comprises well-studied pharmaceuticals with known mechanisms of action, proven efficacy and established safety profiles. This approach results in an efficient, substantially de-risked development process and a rapid regulatory pathway.
The Four Key Advantages of the Chase Approach:
- If successful, Chase’s lead candidate, CPC- 201, will offer a significant improvement over existing therapy and should become the standard-of-care for the symptomatic treatment of Alzheimer’s disease.
- The Chase approach de-risks significant elements of the development process, thus avoiding many of the uncertainties that have plagued past Alzheimer’s drug development. Chase combines existing, well researched pharmaceuticals with known mechanisms of action, proven efficacy and established safety profiles.
- Chase’s pipeline is protected by a strong intellectual property estate spanning five families of composition of matter and related patents.
- CPC-201 should benefit from an efficient and expeditious regulatory pathway in the United States.